E-mail icon E-mail courses Print icon Print course(s)

as of 7/2/2022

Country - Partner Institution - Programs: Netherlands - Utrecht University - 'Utrecht Univ.'
UC Course SubjectBiological Sciences
Number & Suffix: 109
Transcript Title: FUTURE MEDICINES 
UC QTR Units - Division: 6.0 - Upper Division 
Course Description: This course covers advanced therapy medicinal products (ATMP), which include bio molecules and cells, focusing on disease modification and on personal differences: personalized medicine. The following topics are covered: what makes a person a person; which new therapies and vaccines make use of personal differences; can degenerated cells, tissues, and organs be regenerated; which similarities and dissimilarities really matter in patients and medicines; how can costs be controlled. The course starts by looking openly and creatively at the far future in week 1. Which health care innovations do you anticipate in 2050? Small groups prepare and present a presentation. After this science fiction part, the course focuses on present day including which new medicines have been registered in the last few years. Individual students select a drug and write a monograph about all phases of its discovery and development. The following weeks explore the questions of who we are and how we differ which is a discussion of genomics and epigenetics, proteomics and glycomics. The focus is on a molecular level, and on the post translational dynamic reality. This part includes some experimental work: self-typing. In workshops students learn how to read output from genotyping, from proteomics and from glycomic arrays. Innovative therapies and vaccinations, not yet on the market, are studied. This part of the course includes an interview at a biotech company. Small groups of students write a report on the combination of a diagnostic and a therapy. The next topic covered is cell and gene therapy, as well as on regenerative medicine. This part of the course includes a tour at a cell preparation facility. Students discuss solutions to barriers in a final meeting. The final weeks discuss what is sufficiently similar to be useful. What do we expect from biosimilar medicines? And from cell therapy, or from organs, grown in animals? Which patients are similar enough to benefit from the same medicines or cells? This part is closed with a debate about solutions for the problems associated with the current Pharma business model, in a time of ATMP’s. 
Language of Instruction: English
Partner University Department: Pharmaceutical Sciences 
Partner University Course Number: FA-BA314